1
|
Zhang Q, Li L, Lai Y, Zhao T. Silencing of SPP1 Suppresses Progression of Tongue Cancer by Mediating the PI3K/Akt Signaling Pathway. Technol Cancer Res Treat 2020; 19:1533033820971306. [PMID: 33174521 PMCID: PMC7672768 DOI: 10.1177/1533033820971306] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
Background: In the present study, we aimed to find an effective target for the treatment of tongue cancer using gene chip screening and signal pathway research. Methods: We used microarray screening and gene expression profile analyses to find important differentially expressed genes in tongue cancer. We constructed a protein-protein interaction network, and used enrichment analysis of the Kyoto Encyclopedia of Genes and Genomes to screen for important genes. We then silenced the genes of interest in SCC154 cells to study the relationship with the Phosphatidylinositol 3-kinase/Akt signal pathway. Western blot analyses, the 3-(4,5Dimethylthiazol-yl)-2,5Dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide (MTT) test, and immunofluorescence assays were used to compare the expression levels of Phosphatidylinositol 3-kinase/Akt signal pathway-related proteins, cell viability, and cell proliferation ability in normal SCC154 cells, Si-RNA SCC154 cells, and gene-silenced SCC154 cells. The scratch test, Transwell test, and western blotting were used to determine migration, invasion, and carcinogenesis. Results: Using GSE9844, GSE13601, and GSE31056 gene chips, we identified 93 upregulated genes and 76 downregulated genes in tongue cancer. Using the protein-protein interaction network and Kyoto Encyclopedia of Genes and Genomes enrichment analyses, we further identified 47 differentially expressed genes. Using Kaplan-Meier plotter online tools, we also identified 3 genes (SPP1, Recombinant Human Secreted Phosphoprotein 1; PLAU, plasminogen activator urinary; and APP, amyloid precursor protein). Compared with normal SCC154 cells and Si-RNA control SCC154 cells, the expressions of Phosphatidylinositol 3-kinase/Akt pathway proteins in si-SPP1 SCC154 cells were significantly decreased (*P < 0.05), and the protein activities and proliferation abilities were also significantly decreased (*P < 0.05), while the migration ability, invasion ability, and cancer forming ability were significantly increased (*P < 0.05). Conclusion: Inhibition of the SPP1 gene may have a therapeutic effect on tongue cancer, and could be an effective target for the treatment of this disorder.
Collapse
Affiliation(s)
- Qiaoli Zhang
- Department of Stomatology, The First People's Hospital of Fuyang Hangzhou, Hangzhou, Zhejiang, China
| | - Lifeng Li
- Department of Stomatology, The First People's Hospital of Fuyang Hangzhou, Hangzhou, Zhejiang, China
| | - Yueli Lai
- Department of Stomatology, The First People's Hospital of Fuyang Hangzhou, Hangzhou, Zhejiang, China
| | - Tong Zhao
- Department of Stomatology, The First People's Hospital of Fuyang Hangzhou, Hangzhou, Zhejiang, China
| |
Collapse
|
2
|
Chen Y, Gu J, Liu J, Tong L, Shi F, Wang X, Wang X, Yu D, Wu H. Dexamethasone-loaded injectable silk-polyethylene glycol hydrogel alleviates cisplatin-induced ototoxicity. Int J Nanomedicine 2019; 14:4211-4227. [PMID: 31239676 PMCID: PMC6559256 DOI: 10.2147/ijn.s195336] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2018] [Accepted: 04/21/2019] [Indexed: 12/28/2022] Open
Abstract
Background: Cisplatin is an extensively used anti-neoplastic agent for the treatment of various solid tumors. However, a high incidence of severe ototoxicity is accompanied by its use in the clinic. Currently, no drugs or therapeutic strategies have been approved for the treatment of cisplatin-induced ototoxicity by the FDA. Purpose: The purpose of this study was to investigate the otoprotective effects of dexamethasone (DEX)-loaded silk-polyethylene hydrogel (DEX-SILK) following round window membrane administration in the cisplatin-induced ototoxicity mouse model. Methods: The morphology, gelation kinetics, viscosity and secondary structure of the DEX-SILK hydrogel were analyzed. DEX concentration in the perilymph was tested at different time points following hydrogel injection on the RWM niche. Cultured cells (HEI-OC1), organ of Corti explants (C57/BL6, P0-2), and cisplatin-induced hearing loss mice model (C57/BL6) were used as in vitro and in vivo models for investigating the otoprotective effects of DEX-SILK hydrogel against cisplatin. Results: Encapsulation of DEX with a loading of 8% (w/v) did not significantly change the silk gelation time, and DEX was evenly distributed in the Silk-PEG hydrogel as visualized by scanning electron microscopy (SEM). The concentration of Silk majorly influenced DEX distribution, morphological characteristics, viscosity, and gelation time. The optimized DEX-SILK hydrogel (8% w/v loading, 15% silk concentration, 10 μl) was administered directly onto the RWM of the guinea pigs. The DEX concentration in the perilymph was maintained above 1 μg/ml for at least 21 days for the DEX-SILK, while it was maintained for less than 6 h in the control sample of free DEX. DEX-SILK (5-60 ng/ml) exhibited significant protective effects against cisplatin-induced cellular ototoxicity and notably reduced the production of reactive oxygen species (ROS). Eventually, pretreatment with DEX-SILK effectively preserved outer hair cells in the cultured organ of Corti explants and demonstrated significant hearing protection at 4, 8, and 16 kHz in the cisplatin-induced hearing loss mice as compared to the effects noted following pretreatment with DEX. Conclusion: These results demonstrated the clinical value of DEX-SILK for the therapy of cisplatin-induced ototoxicity.
Collapse
Affiliation(s)
- Yuming Chen
- Department of Otolaryngology-Head and Neck Surgery, Shanghai Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200011, People's Republic of China.,Ear Institute, School of Medicine, Shanghai Jiao Tong University, Shanghai 200011, People's Republic of China.,Shanghai Key Laboratory of Translational Medicine on Ear and Nose Diseases (14DZ2260300) , Shanghai 200011, People's Republic of China
| | - Jiayi Gu
- Department of Otolaryngology-Head and Neck Surgery, Shanghai Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200011, People's Republic of China.,Ear Institute, School of Medicine, Shanghai Jiao Tong University, Shanghai 200011, People's Republic of China.,Shanghai Key Laboratory of Translational Medicine on Ear and Nose Diseases (14DZ2260300) , Shanghai 200011, People's Republic of China
| | - Jian Liu
- National Engineering Laboratory for Modern Silk, Soochow University , Suzhou 215123, People's Republic of China
| | - Ling Tong
- Department of Otolaryngology-Head and Neck Surgery, Shanghai Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200011, People's Republic of China
| | - Fuxin Shi
- Department of Otology and Laryngology, Eaton-Peabody Laboratory, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Decibel Therapeutics , Boston, MA, 02215, USA
| | - Xiaoqin Wang
- National Engineering Laboratory for Modern Silk, Soochow University , Suzhou 215123, People's Republic of China
| | - Xueling Wang
- Department of Otolaryngology-Head and Neck Surgery, Shanghai Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200011, People's Republic of China.,Ear Institute, School of Medicine, Shanghai Jiao Tong University, Shanghai 200011, People's Republic of China.,Shanghai Key Laboratory of Translational Medicine on Ear and Nose Diseases (14DZ2260300) , Shanghai 200011, People's Republic of China
| | - Dehong Yu
- Department of Otolaryngology-Head and Neck Surgery, Shanghai Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200011, People's Republic of China.,Ear Institute, School of Medicine, Shanghai Jiao Tong University, Shanghai 200011, People's Republic of China.,Shanghai Key Laboratory of Translational Medicine on Ear and Nose Diseases (14DZ2260300) , Shanghai 200011, People's Republic of China
| | - Hao Wu
- Department of Otolaryngology-Head and Neck Surgery, Shanghai Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200011, People's Republic of China.,Ear Institute, School of Medicine, Shanghai Jiao Tong University, Shanghai 200011, People's Republic of China.,Shanghai Key Laboratory of Translational Medicine on Ear and Nose Diseases (14DZ2260300) , Shanghai 200011, People's Republic of China
| |
Collapse
|